- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Kimberly Park, Vice President Sales and Marketing, PriCara, Ortho-McNeil Janssen Pharmaceuticals
S
Kimberly Park
Vice President Sales and Marketing PriCara, Ortho-McNeil Janssen Pharmaceuticals
TRACK RECORD: Led Merck's managed care group and HIV/AIDS franchise
STARTED OUT: In SmithKline Beckman's management training program
We all have our moments. For Kimberly Park, her moment came when she decided to stay in her high-ranking job—and take on the additional task of being a mother. At first, she says, she wasn't confident that she would be able to manage her priorities. "But I soon realized that I could contribute at the same level—maybe even a higher level—because I became more focused. It was a chance for me to say, 'I'm not perfect, but I can do both.'" Now, Park co-chairs the Women's Leadership Initiative at J&J, where she heads up the company's primary care group. As for the affinity group, Park is proud to note that it's earned it stripes—and it's working. Meanwhile, women in other pharmas have taken a cue, and have set up similar groups at their own companies.
Kimberly Park
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
